Exosome-Mediated Delivery of Transforming Growth Factor-β Receptor 1 Kinase Inhibitors and Toll-Like Receptor 7/8 Agonists for Combination Therapy of Tumors

Combination therapy with the transforming growth factor-β receptor I kinase inhibitor SD-208 and a toll-like receptor-7/8 agonist resiquimod was examined along with serum-derived exosomes as versatile carriers and may serve as a promising strategy to treat melanoma and prostate cancer.